Thymosin Alpha 1: Immune Research & Mechanisms
Thymosin alpha 1 (TA1/Tα1) is a 28-residue acetylated immunomodulatory peptide related to the N-terminal region of prothymosin alpha. It is distinct from the actin-binding thymosin beta-4 family. The most useful scientific distinction is between immune-cell signaling in experimental models and a demonstrated clinical outcome.
TA1 has been studied clinically in several settings, but approval is product-, indication- and jurisdiction-specific. Check the current national product information for the exact medicine and indication. Research-grade material does not inherit the authorization or safety dossier of a pharmaceutical formulation.
What is Thymosin Alpha 1?
TA1 has the sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN. Goldstein and colleagues published its isolation and sequence analysis in 1977. Earlier work on thymosin mixtures should not be cited as the date of isolation of this defined 28-residue molecule.
TA1 and Tβ4 have different sequences and biological roles. “TB-500” also requires a sequence check because suppliers use that label for full Tβ4 or fragments. A shared historical thymosin name does not establish a common mechanism.
Mechanism of Action
TA1’s experimental immune effects involve context-dependent innate and adaptive signaling. A pathway-dependence experiment is not the same as proving direct receptor binding.
Toll-Like-Receptor-Dependent Signaling
Romani et al. (2004) studied dendritic-cell and antifungal responses using Toll-like-receptor/MyD88-related experiments. These findings support a role for that signaling context, but do not independently establish that TA1 directly binds TLR2 or TLR9 as a conventional receptor agonist.
Dendritic Cells and Adaptive Responses
The 2004 experiments included fungi-pulsed dendritic cells and Th1 resistance in transplanted mice. Later work examined dendritic-cell tryptophan catabolism and inflammatory tolerance. “Immune boosting” is too simple a description: the observed response depends on the system and endpoint.
Clinical Outcomes Require Separate Evidence
Changes in immune markers, cell maturation or cytokines do not establish survival benefit in sepsis, viral clearance or cancer efficacy. Each clinical claim needs its own controlled study with a defined product and population.
Clinical Research and Approved Uses
The 2013 ETASS trial randomized 361 patients with severe sepsis in six Chinese hospitals. Its 28-day mortality relative risk was 0.74 (95% CI 0.54-1.02); the nonstratified analysis had P=0.062, while the log-rank analysis had P=0.049. Those different analyses should not be collapsed into an established survival benefit. Its single-blind design and severe-sepsis definition also differ from the later TESTS trial.
The larger TESTS double-blind, placebo-controlled phase 3 trial, published in 2025, randomized 1,106 adults with sepsis and found no conclusive reduction in 28-day mortality. A May 2025 correction updated the primary-outcome hazard ratio to 0.97 (95% CI 0.76–1.24). The correction matters when quoting numerical results.
For hepatitis or any registered use, consult the current national label for the actual pharmaceutical product. Authorization and labelled indications can differ between jurisdictions and formulations.
Pharmacokinetics
PK values depend on the pharmaceutical formulation, dose, route and population. A PK estimate or schedule must be tied to the tested formulation and source protocol.
Do not infer persistence of immune effects directly from a plasma half-life, or assume a hepatitis-product schedule applies to a sepsis experiment or an in-vitro assay. Use the original protocol for the model under study.
Safety Considerations
In TESTS, overall safety outcomes did not differ significantly between the TA1 and placebo groups. That is a result for a defined clinical study, not proof of an “unusually clean” safety record or absence of autoimmune, immunogenicity or long-term risks in all settings.
The FDA’s current risk page identifies inadequate safety information and peptide-impurity/immunogenicity concerns for compounded TA1. A relationship to an endogenous protein does not establish the safety of a research preparation. Confirm the material and lot documentation needed for the intended assay.
Conclusion
TA1 is a distinct immunomodulatory peptide with model-specific immune-signaling findings and controlled clinical research. The large 2025 sepsis trial did not establish a 28-day mortality benefit. Keep mechanistic evidence, clinical outcomes and product authorization separate when selecting a study model or interpreting the literature.
Source this peptide for your research
Order Thymosin Alpha-1Frequently Asked Questions
What is the difference between Thymosin Alpha 1, Thymosin Beta-4, and TB-500?
TA1 is a 28-residue immunomodulatory peptide. Full thymosin beta-4 is a 43-residue actin-binding peptide. “TB-500” is a trade name used for full Tβ4 or a smaller fragment; inspect the sequence. The shared name does not make these materials interchangeable.
Is Thymosin Alpha 1 approved as a drug?
Authorization is specific to the pharmaceutical product, indication and country. FDA’s compounding safety-risk discussion is not therapeutic approval, and a research TA1 vial does not inherit a pharmaceutical product’s authorization.
Is Thymosin Alpha 1 orally active?
The clinical sepsis trials used subcutaneous administration. Those sources do not establish a validated oral formulation or regimen for research-grade TA1. Consult the route and formulation actually tested rather than assuming equivalence.
What purity standard should research-grade Thymosin Alpha 1 meet?
Review the lot-specific report for the exact sequence, modifications, HPLC method/trace and interpreted MS result. A compatible intact mass supports composition but is not complete sequence confirmation. If stock concentration matters, obtain a quantitative target-content basis; HPLC area purity is separate from net content. Select acceptance criteria for the model rather than assuming one percentage measures every quality attribute.
What is the half-life of Thymosin Alpha 1?
The references in this article do not establish a universal half-life for all supplied TA1 material. PK and immune-response persistence are separate measurements, and any numerical statement should identify the tested formulation, route and population.
Scientific References
- Goldstein et al. 1977. TA1 isolation and sequence analysis. PMID: 265536 - Primary source[PubMed Reference]
- Romani et al. 2004. Dendritic cells and Toll-like receptor signaling. PMID: 14982877 - Primary source[PubMed Reference]
- Romani et al. 2006. Dendritic-cell tryptophan catabolism and tolerance. PMID: 16741252 - Primary source[PubMed Reference]
- Wu et al. 2025. TESTS randomized phase 3 trial. PMID: 39814420 - Primary source[PubMed Reference]
- TESTS correction, May 2025. PMID: 40447307 - Primary source[PubMed Reference]
- FDA current TA1 compounding safety-risk page - Primary source
- Wu et al. 2013. ETASS multicentre single-blind severe-sepsis trial. PMID: 23327199 - Primary source[PubMed Reference]
Related Research Peptides
Thymosin Beta-4 5mg
